Abstract
Parkinsons disease (PD) is a common neurodegenerative disease, characterized by a selective loss of midbrain dopaminergic (DA) neurons. To address this problem, various types of stem cells that have potential to differentiate into DA neurons are being investigated as cellular therapies for PD, including cells derived from embryonic or adult donor tissue, and embryonic stem cells. These cell sources, however. have raised certain questions with regard to ethical and rejection issues. Recent progress in adult stems has further proved that the cells derived from adult tissue could be expanded and differentiated into DA precursor cells in vitro, and cell therapy with adult stem cells could produce a clear improvement for PD models. Using adult stem cells for clinic application may not only overcome the ethical problem inherent in using human fetal tissue or embryonic stem cells, but also open the possibility for autologous transplantation. The patient-specific adult stem cell is therefore a potential and prospective candidate for PD treatment.
Keywords: Parkinson's disease, dopaminergic neurons, adult stem cells, neural stem cells, induced pluripotent stem cells, embryonic stem cells, mesenchymal stem cells, carotid body stem cells, cell transplantation therapy, fetal stem cells, FOXA2
CNS & Neurological Disorders - Drug Targets
Title: Emerging Restorative Treatments for Parkinsons Disease: Manipulation and Inducement of Dopaminergic Neurons from Adult Stem Cells
Volume: 10 Issue: 4
Author(s): Junpeng Zhao and Qunyuan Xu
Affiliation:
Keywords: Parkinson's disease, dopaminergic neurons, adult stem cells, neural stem cells, induced pluripotent stem cells, embryonic stem cells, mesenchymal stem cells, carotid body stem cells, cell transplantation therapy, fetal stem cells, FOXA2
Abstract: Parkinsons disease (PD) is a common neurodegenerative disease, characterized by a selective loss of midbrain dopaminergic (DA) neurons. To address this problem, various types of stem cells that have potential to differentiate into DA neurons are being investigated as cellular therapies for PD, including cells derived from embryonic or adult donor tissue, and embryonic stem cells. These cell sources, however. have raised certain questions with regard to ethical and rejection issues. Recent progress in adult stems has further proved that the cells derived from adult tissue could be expanded and differentiated into DA precursor cells in vitro, and cell therapy with adult stem cells could produce a clear improvement for PD models. Using adult stem cells for clinic application may not only overcome the ethical problem inherent in using human fetal tissue or embryonic stem cells, but also open the possibility for autologous transplantation. The patient-specific adult stem cell is therefore a potential and prospective candidate for PD treatment.
Export Options
About this article
Cite this article as:
Zhao Junpeng and Xu Qunyuan, Emerging Restorative Treatments for Parkinsons Disease: Manipulation and Inducement of Dopaminergic Neurons from Adult Stem Cells, CNS & Neurological Disorders - Drug Targets 2011; 10 (4) . https://dx.doi.org/10.2174/187152711795563921
DOI https://dx.doi.org/10.2174/187152711795563921 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Current Medicinal Chemistry New Perspectives in the Pharmacological Potential of Naringin in Medicine
Current Medicinal Chemistry Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Platelet Microparticles Induce Angiogenesis and Neurogenesis after Cerebral Ischemia
Current Neurovascular Research Mitochondria-Targeted Drugs
Current Molecular Pharmacology Harvesting New Therapeutic Avenues with Stem Cell Applications
Current Neurovascular Research Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Microdialysis-Assessed Adipose Tissue Metabolism in Critically Ill Patients
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Zolpidem Arousing Effect in Persistent Vegetative State Patients: Autonomic, EEG and Behavioral Assessment
Current Pharmaceutical Design Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy Nanomedicines for Brain Targeting: A Patent Review
Recent Patents on Nanomedicine Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design Stroke Induced Immunodepression Syndrome: From Bench to Bedside
Current Molecular Medicine Oxidative Stress and Amyloid Beta Toxicity in Alzheimer’s Disease: Intervention in a Complex Relationship by Antioxidants
Current Medicinal Chemistry Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Neurotransmitters and Microglial-Mediated Neuroinflammation
Current Protein & Peptide Science